{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:26:18Z","timestamp":1787293578204,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02901-8","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:54:47Z","timestamp":1778061287000},"page":"2327-2338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mining safety signals of PD-1\/PD-L1 inhibitor-related adrenal insufficiency: a study based on the FAERS database"],"prefix":"10.1007","volume":"49","author":[{"given":"Ruoxuan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"3","key":"2901_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2901_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172","journal-title":"Science"},{"key":"2901_CR3","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA et al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2901_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2901_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2901_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"2901_CR7","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"2901_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ et al (2017) Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev 58:70\u201376. https:\/\/doi.org\/10.1016\/j.ctrv.2017.06.002","journal-title":"Cancer Treat Rev"},{"key":"2901_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219\u2013242. https:\/\/doi.org\/10.1111\/j.1600-065X.2010.00923.x","journal-title":"Immunol Rev"},{"issue":"1","key":"2901_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40291-017-0308-6","volume":"22","author":"K Ancevski Hunter","year":"2018","unstructured":"Ancevski Hunter K, Socinski MA, Villaruz LC (2018) PD-L1 Testing in Guiding Patient Selection for PD-1\/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22(1):1\u201310. https:\/\/doi.org\/10.1007\/s40291-017-0308-6","journal-title":"Mol Diagn Ther"},{"issue":"10","key":"2901_CR11","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/diagnostics13101812","volume":"13","author":"S Shaikh","year":"2023","unstructured":"Shaikh S, Nagendra L, Shaikh S et al (2023) Adrenal Failure: An Evidence-Based Diagnostic Approach. Diagnostics (Basel) 13(10):1812. https:\/\/doi.org\/10.3390\/diagnostics13101812","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"2901_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7):389\u2013399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2901_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7 (2017) An overview and management of osteoporosis. Eur J Rheumatol 4(1):46\u201356. https:\/\/doi.org\/10.5152\/eurjrheum.2016.048","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"2901_CR14","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","volume":"11","author":"Y Jing","year":"2020","unstructured":"Jing Y, Liu J, Ye Y et al (2020) Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun 11(1):4946. https:\/\/doi.org\/10.1038\/s41467-020-18742-9","journal-title":"Nat Commun"},{"issue":"10","key":"2901_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A et al (2013) Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf 36(10):995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7","journal-title":"Drug Saf"},{"issue":"1","key":"2901_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.2920","volume":"114","author":"S Xia","year":"2023","unstructured":"Xia S, Gong H, Zhao Y et al (2023) Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database. Clin Pharmacol Ther 114(1):211\u2013219. https:\/\/doi.org\/10.1002\/cpt.2920","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2901_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zheng Y, Xu B et al (2024) Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. BMC Med 22(1):65. https:\/\/doi.org\/10.1186\/s12916-024-03274-6","journal-title":"BMC Med"},{"issue":"5","key":"2901_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Tachi T, Teramachi H (2020) Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems. Pharm Res 37(5):86. https:\/\/doi.org\/10.1007\/s11095-020-02801-3","journal-title":"Pharm Res"},{"issue":"4","key":"2901_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/clpt.2010.111","volume":"88","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Thiessard F, Miremont-Salam\u00e9 G et al (2010) Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study. Clin Pharmacol Ther 88(4):492\u2013498. https:\/\/doi.org\/10.1038\/clpt.2010.111","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2901_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.23785\/PRAXIS.2025.04.005","volume":"114","author":"SF Borsari","year":"2025","unstructured":"Borsari SF, Bilz S (2025) Medikament\u00f6s induzierte Nebenniereninsuffizienz [Drug-induced adrenal insufficiency]. Praxis (Bern 1994) 114(4):149\u2013153. https:\/\/doi.org\/10.23785\/PRAXIS.2025.04.005","journal-title":"Praxis (Bern 1994)"},{"issue":"5","key":"2901_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H et al (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother 15(5):1111\u20131122. https:\/\/doi.org\/10.1080\/21645515.2019.1571892","journal-title":"Hum Vaccin Immunother"},{"key":"2901_CR22","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-20-2127","volume":"26","author":"DY Wang","year":"2020","unstructured":"Wang DY, Johnson DB, ,Davis EJ (2020) Reporting rates of immune-related adverse events underestimate their true incidence in cancer clinical trials. Clin Cancer Res 26:6267\u20136273. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2127","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2901_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K et al (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"2901_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1056\/NEJMoa1915745","volume":"160","author":"G Wick","year":"1997","unstructured":"Wick G, Grubeck-Loebenstein B (1997) Primary and secondary alterations of immune reactivity in the elderly: impact of dietary factors and disease. Immunol Rev 160:171\u2013184. https:\/\/doi.org\/10.1111\/j.1600-065x.1997.tb01037","journal-title":"Immunol Rev"},{"issue":"1","key":"2901_CR25","doi-asserted-by":"publisher","first-page":"10440","DOI":"10.1038\/s41598-019-46849-7","volume":"9","author":"H Kang","year":"2019","unstructured":"Kang H, Hong SH (2019) Risk of Kidney Dysfunction from Polypharmacy among Older Patients: A Nested Case-Control Study of the South Korean Senior Cohort. Sci Rep 9(1):10440. https:\/\/doi.org\/10.1038\/s41598-019-46849-7","journal-title":"Sci Rep"},{"key":"2901_CR26","doi-asserted-by":"publisher","first-page":"756872","DOI":"10.3389\/fimmu.2021.756872","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W, Ma F, Sun B et al (2021) Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study. Front Immunol 12:756872. https:\/\/doi.org\/10.3389\/fimmu.2021.756872","journal-title":"Front Immunol"},{"issue":"20","key":"2901_CR27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382(20):1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"issue":"21","key":"2901_CR28","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 379(21):2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"issue":"1","key":"2901_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EDM-19-0047","volume":"2019","author":"P Kempegowda","year":"2019","unstructured":"Kempegowda P, Quinn L, Shepherd L et al (2019) Adrenal insufficiency from steroid-containing complementary therapy: importance of detailed history. Endocrinol Diabetes Metab Case Rep 2019(1):1\u20134. https:\/\/doi.org\/10.1530\/EDM-19-0047","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2901_CR30","doi-asserted-by":"publisher","first-page":"1691740","DOI":"10.3389\/fendo.2025.1691740","volume":"16","author":"S Monti","year":"2026","unstructured":"Monti S, Fazzalari B, Renzelli V et al (2026) Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency. Front Endocrinol (Lausanne) 16:1691740. https:\/\/doi.org\/10.3389\/fendo.2025.1691740","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2901_CR31","doi-asserted-by":"publisher","first-page":"107476","DOI":"10.1016\/j.ejps.2026.107476","volume":"219","author":"X Chen","year":"2026","unstructured":"Chen X, Chen C, Zhang Y et al (2026) Activating antigen-specific T cells by the dual action of paclitaxel to enhance tumor immunotherapy. Eur J Pharm Sci 219:107476. https:\/\/doi.org\/10.1016\/j.ejps.2026.107476","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"2901_CR32","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/MAJ.0b013e3181db6b7a","volume":"339","author":"B Bleicken","year":"2010","unstructured":"Bleicken B, Hahner S, Ventz M, Quinkler M (2010) Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci 339(6):525\u2013531. https:\/\/doi.org\/10.1097\/MAJ.0b013e3181db6b7a","journal-title":"Am J Med Sci"},{"issue":"3","key":"2901_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/s2213-8587(14)70142-1","volume":"3","author":"I Bancos","year":"2015","unstructured":"Bancos I, Hahner S, Tomlinson J et al (2015) Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol 3(3):216\u2013226. https:\/\/doi.org\/10.1016\/s2213-8587(14)70142-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2901_CR34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W et al (2016) Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101(2):364\u2013389. https:\/\/doi.org\/10.1210\/jc.2015-1710","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2901_CR35","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/jco.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02901-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02901-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:08:53Z","timestamp":1787292533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02901-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2901"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02901-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We hereby confirm that the data utilized in our study were obtained from publicly available databases. As such, the nature of these datasets precludes the need for ethical committee review and the collection of informed consent from individual participants. The data were collected and made publicly accessible by entities unrelated to our research, and we have ensured that our use of these data complies with all relevant legal and ethical guidelines. We acknowledge the importance of ethical considerations in research and the protection of human subjects. However, in the case of public databases, these typically do not require the same level of oversight that would be necessary for primary data collection involving human participants. Our study design and analysis were conducted with the utmost respect for privacy and the ethical use of data, and we are committed to maintaining the highest standards of research integrity.","order":2,"name":"Ethics","label":"Statement on Data Source and Ethical Considerations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.","order":3,"name":"Ethics","label":"Publisher\u2019s note","group":{"name":"EthicsHeading","label":"Declarations"}}]}}